| Title |
Pre-clinical characterization of CX-4945, a potent and selective small molecule inhibitor of CK2 for the treatment of cancer
|
|---|---|
| Published in |
Molecular and Cellular Biochemistry, July 2011
|
| DOI | 10.1007/s11010-011-0956-5 |
| Pubmed ID | |
| Authors |
Fabrice Pierre, Peter C. Chua, Sean E. O’Brien, Adam Siddiqui-Jain, Pauline Bourbon, Mustapha Haddach, Jerome Michaux, Johnny Nagasawa, Michael K. Schwaebe, Eric Stefan, Anne Vialettes, Jeffrey P. Whitten, Ta Kung Chen, Levan Darjania, Ryan Stansfield, Joshua Bliesath, Denis Drygin, Caroline Ho, May Omori, Chris Proffitt, Nicole Streiner, William G. Rice, David M. Ryckman, Kenna Anderes |
| Abstract |
In this article we describe the preclinical characterization of 5-(3-chlorophenylamino) benzo[c][2,6]naphthyridine-8-carboxylic acid (CX-4945), the first orally available small molecule inhibitor of protein CK2 in clinical trials for cancer. CX-4945 was optimized as an ATP-competitive inhibitor of the CK2 holoenzyme (Ki = 0.38 nM). Iterative synthesis and screening of analogs, guided by molecular modeling, led to the discovery of orally available CX-4945. CK2 promotes signaling in the Akt pathway and CX-4945 suppresses the phosphorylation of Akt as well as other key downstream mediators of the pathway such as p21. CX-4945 induced apoptosis and caused cell cycle arrest in cancer cells in vitro. CX-4945 exhibited a dose-dependent antitumor activity in a xenograft model of PC3 prostate cancer model and was well tolerated. In vivo time-dependent reduction in the phosphorylation of the biomarker p21 at T145 was observed by immunohistochemistry. Inhibition of the newly validated CK2 target by CX-4945 represents a fresh therapeutic strategy for cancer. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 87 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Japan | 1 | 1% |
| United States | 1 | 1% |
| Canada | 1 | 1% |
| Unknown | 84 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 21 | 24% |
| Researcher | 11 | 13% |
| Student > Bachelor | 11 | 13% |
| Student > Master | 9 | 10% |
| Student > Doctoral Student | 4 | 5% |
| Other | 14 | 16% |
| Unknown | 17 | 20% |
| Readers by discipline | Count | As % |
|---|---|---|
| Agricultural and Biological Sciences | 24 | 28% |
| Biochemistry, Genetics and Molecular Biology | 20 | 23% |
| Chemistry | 8 | 9% |
| Medicine and Dentistry | 8 | 9% |
| Immunology and Microbiology | 2 | 2% |
| Other | 8 | 9% |
| Unknown | 17 | 20% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 24 July 2014.
All research outputs
#15,303,056
of 22,758,963 outputs
Outputs from Molecular and Cellular Biochemistry
#1,316
of 2,295 outputs
Outputs of similar age
#84,090
of 116,976 outputs
Outputs of similar age from Molecular and Cellular Biochemistry
#17
of 24 outputs
Altmetric has tracked 22,758,963 research outputs across all sources so far. This one is in the 22nd percentile – i.e., 22% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,295 research outputs from this source. They receive a mean Attention Score of 3.9. This one is in the 35th percentile – i.e., 35% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 116,976 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 17th percentile – i.e., 17% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 24 others from the same source and published within six weeks on either side of this one. This one is in the 29th percentile – i.e., 29% of its contemporaries scored the same or lower than it.